Cantargia
3.82 SEK
+0.53 %
1,289 following
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+0.53 %
+16.64 %
+47.49 %
+228.18 %
+126.04 %
+111.99 %
+13.83 %
-92.78 %
-45.95 %
Cantargia operates in the pharmaceutical industry and focuses on the development of treatments for cancer and inflammatory diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Cantargia was founded in 2009 and is headquartered in Lund, Sweden.
Read moreMarket cap
949.7M SEK
Turnover
22.2M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
20.2
2026
Annual report '25
19.5
2026
Interim report Q1'26
21.5
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Redeye: Cantargia (Q3 Review) - Planning for a Pivotal Study of Nadunolimab
Cantargia, Audiocast, Q3'25
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
